| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anastasia Geladaris, Sebastian Torke, Darius Saberi, Yasemin B Alankus, Frank Streit, Sabrina Zechel, Christine Stadelmann-Nessler, Andreas Fischer, Ursula Boschert, Darius Häusler, Martin S Webe. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair. Acta neuropathologica. vol 147. issue 1. 2024-04-24. PMID:38656399. |
one promising strategy to control progression of ms is the inhibition of the enzyme bruton's tyrosine kinase (btk), which is centrally involved in the activation of both b cells and myeloid cells, such as macrophages and microglia. |
2024-04-24 |
2024-04-28 |
Not clear |
| Anastasia Geladaris, Sebastian Torke, Darius Saberi, Yasemin B Alankus, Frank Streit, Sabrina Zechel, Christine Stadelmann-Nessler, Andreas Fischer, Ursula Boschert, Darius Häusler, Martin S Webe. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair. Acta neuropathologica. vol 147. issue 1. 2024-04-24. PMID:38656399. |
additionally, in a model of toxic demyelination, evobrutinib-mediated btk inhibition promoted the clearance of myelin debris by microglia, leading to an accelerated remyelination. |
2024-04-24 |
2024-04-28 |
Not clear |
| Anastasia Geladaris, Sebastian Torke, Darius Saberi, Yasemin B Alankus, Frank Streit, Sabrina Zechel, Christine Stadelmann-Nessler, Andreas Fischer, Ursula Boschert, Darius Häusler, Martin S Webe. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair. Acta neuropathologica. vol 147. issue 1. 2024-04-24. PMID:38656399. |
the benefit of btk inhibition by evobrutinib was shown as we observed reduced pro-inflammatory activation of microglia when treating chronic experimental autoimmune encephalomyelitis (eae) or following the adoptive transfer of activated t cells. |
2024-04-24 |
2024-04-28 |
Not clear |
| Laura Airas, Robert A Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J Williams, Bernd C Kieseier, Heinz Wiend. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Therapeutic advances in neurological disorders. vol 17. 2024-04-19. PMID:38638671. |
btk is expressed in b-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ms pathogenesis, along with mast cells, establishing the relevance of btk inhibitors to diverse autoimmune conditions. |
2024-04-19 |
2024-04-21 |
Not clear |
| Julia Krämer, Heinz Wiend. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations. Current opinion in neurology. 2024-03-27. PMID:38533819. |
bruton tyrosine kinase (btk) is an intracellular signaling molecule involved in regulation of maturation, survival, migration, and activation of b cells and microglia, which are central players in the immunopathogenesis of progressive ms. |
2024-03-27 |
2024-03-29 |
Not clear |
| Anja Steinmaurer, Christian Riedl, Theresa König, Giulia Testa, Ulrike Köck, Jan Bauer, Hans Lassmann, Romana Höftberger, Thomas Berger, Isabella Wimmer, Simon Hametne. The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis. Brain pathology (Zurich, Switzerland). 2024-01-23. PMID:38254312. |
here, we investigated the protein expression of btk and cd68 as well as iron accumulation in postmortem control (n = 10) and ms (n = 23) brain tissue, focusing on microglia and macrophages. |
2024-01-23 |
2024-01-25 |
Not clear |
| Anja Steinmaurer, Christian Riedl, Theresa König, Giulia Testa, Ulrike Köck, Jan Bauer, Hans Lassmann, Romana Höftberger, Thomas Berger, Isabella Wimmer, Simon Hametne. The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis. Brain pathology (Zurich, Switzerland). 2024-01-23. PMID:38254312. |
in vitro, btk inhibition resulted in reduced phagocytic activity and modulated btk-dependent inflammatory signaling of microglia and macrophages. |
2024-01-23 |
2024-01-25 |
Not clear |
| Maria L Elkjaer, Mie R Waede, Christina Kingo, Karina Damsbo, Zsolt Ille. Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. Frontiers in immunology. vol 14. 2023-12-01. PMID:38022591. |
btk inhibitors (btki) cross the blood-brain barrier and modulate b cells and microglia, major cellular players in active and chronic active lesions. |
2023-12-01 |
2023-12-07 |
Not clear |
| Maria L Elkjaer, Mie R Waede, Christina Kingo, Karina Damsbo, Zsolt Ille. Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. Frontiers in immunology. vol 14. 2023-12-01. PMID:38022591. |
btk inhibitors (btki) cross the blood-brain barrier and modulate b cells and microglia, major cellular players in active and chronic active lesions. |
2023-11-29 |
2023-12-07 |
Not clear |
| Chengli Liu, Kun Yao, Qi Tian, Yujia Guo, Guijun Wang, Peibang He, Jianfeng Wang, Jian Wang, Zhan Zhang, Mingchang L. CXCR4-BTK axis mediate pyroptosis and lipid peroxidation in early brain injury after subarachnoid hemorrhage via NLRP3 inflammasome and NF-κB pathway. Redox biology. vol 68. 2023-11-18. PMID:37979447. |
inhibition of btk phosphorylation promoted the in vitro transition of hemin-treated proinflammatory microglia to the anti-inflammatory state, inhibited the p-p65 expression and microglial pyroptosis. |
2023-11-18 |
2023-11-20 |
mouse |
| Benjamin M Greenber. Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier. Neurologic clinics. vol 42. issue 1. 2023-11-18. PMID:37980113. |
bruton's tyrosine kinase (btk) is an enzyme that mediates b cell activation and the proinflammatory phenotype of microglia. |
2023-11-18 |
2023-11-20 |
Not clear |
| Darius Saberi, Anastasia Geladaris, Sarah Dybowski, Martin S Webe. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis. Expert opinion on therapeutic targets. 2023-06-05. PMID:37272515. |
in this context, bruton's tyrosine kinase (btk) inhibition may be a promising therapeutic approach, as the enzyme is centrally involved in the activation of b cells as well as myeloid cells, such as macrophages and microglia. |
2023-06-05 |
2023-08-14 |
Not clear |
| Julia Krämer, Amit Bar-Or, Timothy J Turner, Heinz Wiend. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature reviews. Neurology. 2023-04-13. PMID:37055617. |
as cns-compartmentalized b cells and microglia are considered central to the immunopathogenesis of progressive ms, treatment with cns-penetrant btk inhibitors might curtail disease progression by targeting immune cells on both sides of the blood-brain barrier. |
2023-04-13 |
2023-08-14 |
Not clear |
| Julia Krämer, Amit Bar-Or, Timothy J Turner, Heinz Wiend. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature reviews. Neurology. 2023-04-13. PMID:37055617. |
bruton tyrosine kinase (btk) is an intracellular signalling molecule involved in the regulation of maturation, survival, migration and activation of b cells and microglia. |
2023-04-13 |
2023-08-14 |
Not clear |
| Anastasia Geladaris, Sebastian Torke, Martin S Webe. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression? CNS drugs. 2022-09-30. PMID:36178589. |
in this regard, one promising strategy may be the inhibition of the enzyme bruton's tyrosine kinase (btk), which is centrally involved in the activation of b cells as well as myeloid cells, such as macrophages and microglia. |
2022-09-30 |
2023-08-14 |
Not clear |
| Shane Arsenault, Rochelle Y Benoit, Fraser Clift, Craig S Moor. Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis? Multiple sclerosis and related disorders. vol 67. 2022-09-20. PMID:36126539. |
the highly selective irreversible bruton tyrosine kinase (btk) inhibitors evobrutinib, tolebrutinib, and orelabrutinib, and the reversible btk inhibitor fenebrutinib, all target b-cell activation and aspects of innate immunity, including macrophage and microglia biology. |
2022-09-20 |
2023-08-14 |
Not clear |
| Kathryn Pellerin, Stephen J Rubino, Jeremy C Burns, Benjamin A Smith, Christie-Ann McCarl, Jing Zhu, Luke Jandreski, Patrick Cullen, Thomas M Carlile, Angela Li, Jorge Vera Rebollar, Jennifer Sybulski, Taylor L Reynolds, Baohong Zhang, Rebecca Basile, Hao Tang, Chelsea Parker Harp, Alex Pellerin, John Silbereis, Nathalie Franchimont, Ellen Cahir-McFarland, Richard M Ransohoff, Thomas O Cameron, Michael Minguenea. MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response. Brain : a journal of neurology. vol 144. issue 8. 2021-12-08. PMID:34145876. |
together, these results establish a physiologically-meaningful functional response to fc receptor and btk signalling in microglia, while providing a novel in vivo tool to further dissect the roles of microglia-specific fc receptor and btk-driven responses to both pathogenic and therapeutic antibodies in cns homeostasis and disease. |
2021-12-08 |
2023-08-13 |
mouse |
| Kathryn Pellerin, Stephen J Rubino, Jeremy C Burns, Benjamin A Smith, Christie-Ann McCarl, Jing Zhu, Luke Jandreski, Patrick Cullen, Thomas M Carlile, Angela Li, Jorge Vera Rebollar, Jennifer Sybulski, Taylor L Reynolds, Baohong Zhang, Rebecca Basile, Hao Tang, Chelsea Parker Harp, Alex Pellerin, John Silbereis, Nathalie Franchimont, Ellen Cahir-McFarland, Richard M Ransohoff, Thomas O Cameron, Michael Minguenea. MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response. Brain : a journal of neurology. vol 144. issue 8. 2021-12-08. PMID:34145876. |
downstream of the fc receptors, btk was a required signalling node for this response, as microglia proliferation was amplified in btke41k knock-in mice expressing a constitutively active form of the enzyme and blunted in mice treated with a cns-penetrant small molecule inhibitor of btk. |
2021-12-08 |
2023-08-13 |
mouse |
| Timothy D Owens, Patrick F Smith, Andrew Redfern, Yan Xing, Jin Shu, Dane E Karr, Sonja Hartmann, Michelle R Francesco, Claire L Langrish, Philip A Nunn, Steven G Gourla. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clinical and translational science. 2021-11-12. PMID:34724345. |
bruton's tyrosine kinase (btk), expressed in b cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the b-cell receptor and fc-receptors. |
2021-11-12 |
2023-08-13 |
Not clear |
| Anja Steinmaurer, Isabella Wimmer, Thomas Berger, Paulus Stefan Rommer, Johann Sellne. Bruton's tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis. Current pharmaceutical design. 2021-07-05. PMID:34218776. |
moreover, brain-penetrant btk inhibitors may impact compartmentalized inflammation and neurodegeneration within the central nervous system by targeting brain-resident b cells and microglia, respectively. |
2021-07-05 |
2023-08-13 |
Not clear |